Sernova Future Growth

Future criteria checks 5/6

Sernova is forecast to grow earnings and revenue by 61.4% and 60.2% per annum respectively while EPS is expected to grow by 60.4% per annum.

Key information

61.4%

Earnings growth rate

60.4%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	60.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:SEOV.F - Analysts future estimates and past financials data (CAD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
10/31/2027	76	26	N/A	N/A	2
10/31/2026	0	-27	N/A	N/A	3
10/31/2025	10	-16	-1	-1	3
10/31/2024	N/A	-38	-23	-23	4
7/31/2024	N/A	-39	-26	-26	N/A
4/30/2024	N/A	-41	-27	-27	N/A
1/31/2024	N/A	-41	-29	-29	N/A
10/31/2023	N/A	-39	-30	-30	N/A
7/31/2023	N/A	-36	-24	-24	N/A
4/30/2023	N/A	-31	-24	-24	N/A
1/31/2023	N/A	-27	-18	-18	N/A
10/31/2022	N/A	-24	-15	-14	N/A
7/31/2022	N/A	-18	-12	-12	N/A
4/30/2022	N/A	-14	-9	-9	N/A
1/31/2022	N/A	-11	-8	-8	N/A
10/31/2021	N/A	-7	-7	-7	N/A
7/31/2021	N/A	-6	-6	-6	N/A
4/30/2021	N/A	-5	-6	-5	N/A
1/31/2021	N/A	-5	-5	-4	N/A
10/31/2020	N/A	-5	-5	-4	N/A
7/31/2020	N/A	-6	-6	-5	N/A
4/30/2020	N/A	-6	-5	-5	N/A
1/31/2020	N/A	-5	-5	-5	N/A
10/31/2019	N/A	-4	-4	-4	N/A
7/31/2019	N/A	-3	-3	-3	N/A
4/30/2019	N/A	-3	-4	-4	N/A
1/31/2019	N/A	-4	-4	-4	N/A
10/31/2018	N/A	-4	-4	-4	N/A
7/31/2018	N/A	-4	-4	-3	N/A
4/30/2018	N/A	-3	N/A	-3	N/A
1/31/2018	N/A	-3	N/A	-3	N/A
10/31/2017	N/A	-3	N/A	-3	N/A
7/31/2017	N/A	-2	N/A	-3	N/A
4/30/2017	N/A	-2	N/A	-3	N/A
1/31/2017	N/A	-2	N/A	-3	N/A
10/31/2016	N/A	-2	N/A	-3	N/A
7/31/2016	N/A	-3	N/A	-2	N/A
4/30/2016	N/A	-3	N/A	-2	N/A
1/31/2016	N/A	-3	N/A	-2	N/A
10/31/2015	N/A	-3	N/A	-2	N/A
7/31/2015	N/A	-3	N/A	-2	N/A
4/30/2015	N/A	-3	N/A	-2	N/A
1/31/2015	N/A	-3	N/A	-2	N/A
10/31/2014	N/A	-3	N/A	-2	N/A
7/31/2014	N/A	-3	N/A	-1	N/A
4/30/2014	N/A	-2	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SEOV.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: SEOV.F is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SEOV.F is expected to become profitable in the next 3 years.

Revenue vs Market: SEOV.F's revenue (60.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: SEOV.F's revenue (60.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SEOV.F's Return on Equity is forecast to be high in 3 years time

Sernova Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

Sernova Corp. Announces Executive Changes

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies